As a result, alternative therapies, such as ACE inhibitors (32.8%) and angiotensin II type 1 receptor antagonists (AT1RAs) (6.6%), are utilized at our institute for the management of SSc-RP and DUs. The gene discussed is ACE; the disease is systemic sclerosis.